SEP 8, 2026 · PHASE 3 TRIAL
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
ClinicalTrials.gov
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
Reported
Estimated enrollment600
PhasePhase 3
Primary endpoint 1Progression-Free Survival (PFS), up to appr…